Low dose novel PARP-PI3K inhibition via nanoformulation improves colorectal cancer immunoradiotherapy
Open Access
- 1 September 2020
- journal article
- research article
- Published by Elsevier in Materials Today Bio
- Vol. 8, 100082
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Biomedical Imaging and Bioengineering (1R15EB021581-01)
- Oregon State University
- Deutsche Forschungsgemeinschaft (326998133 TRR 225, 398461692)
- National Institute of General Medical Sciences (1R35GM119839-01)
This publication has 60 references indexed in Scilit:
- Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cellsCancer Letters, 2013
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP InhibitionCancer Discovery, 2012
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast CancerCancer Discovery, 2012
- Cytoplasmic vacuolization during exposure to drugs and other substancesCell Biology and Toxicology, 2012
- Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on sizeNature Nanotechnology, 2011
- Structure-property relationship in cytotoxicity and cell uptake of poly(2-oxazoline) amphiphilesJournal of Controlled Release, 2011
- A 3-in-1 Polymeric Micelle Nanocontainer for Poorly Water-Soluble DrugsMolecular Pharmaceutics, 2011
- Immunogenic death of colon cancer cells treated with oxaliplatinOncogene, 2009
- Role of oxaliplatin in the treatment of colorectal cancerTherapeutics and Clinical Risk Management, 2009
- Novel formulations of taxanes: a review. Old wine in a new bottle?Annals of Oncology, 2005